Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients

被引:21
作者
Naesens, Maarten
Verbeke, Kristin
Vanrenterghem, Yves
Kuypers, Dirk
机构
[1] Univ Hosp Leuven, Dept Nephrol & Renal Transplantat, B-3000 Louvain, Belgium
[2] Catholic Univ Louvain, Dept Gastrointestinal Res, B-3000 Louvain, Belgium
关键词
absorption; gastric emptying; mycophenolic acid pharmacokinetics; therapeutic drug monitoring;
D O I
10.1111/j.1365-2125.2006.02813.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim To investigate the effect of gastric emptying on the pharmacokinetics of mycophenolic acid (MPA) in renal transplant patients. Methods We assessed the effect of gastric emptying on the disposition of MPA in 27 stable renal allograft recipients at 2 years after transplantation. Gastric emptying was measured by the C-14-octanoate and C-13-glycine breath test. Results Delayed gastric emptying was associated with a significantly longer MPA t(max) [1.0 (0.33-2.0) h vs. 0.5 (0.33-1.0) h; mean difference 0.39 h, 95% confidence interval (CI) 0.03, 0.75; P = 0.0289] and with a significant decrease in the maximum MPA concentration after dosing [10.6 (6.5-21.3) mg l(-1)vs. 20.1 (10.7-28.5) mg l(-1); mean difference 6.5 mg l(-1), 95% CI 2.1, 10.9; P = 0.0075]. Despite the substantial effect of delayed gastric emptying rates on MPA C-max and t(max), total dose-interval exposure, measured by the MPA AUC(0-4), was not affected by the rate of gastric emptying [20.4 (13.9-43.0) mg h(-1) l(-1)vs. 22.4 (13.1-29.8) mg h(-1) l(-1)]. Conclusion Delayed gastric emptying was associated with a slower absorption of MPA, a longer time to reach peak concentrations and lower maximum concentrations. These effects should be taken into account when validating limited (< 2 h) sampling strategies to estimate total MPA exposure, which could be unreliable when monitoring patients with gastric emptying disorders.
引用
收藏
页码:541 / 547
页数:7
相关论文
共 27 条
[1]   Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients [J].
Akhlaghi, F ;
Patel, CG ;
Zuniga, XP ;
Halilovic, D ;
Preis, IS ;
Gohh, RY .
THERAPEUTIC DRUG MONITORING, 2006, 28 (01) :95-101
[2]   Mycophenolate mofetil and its mechanisms of action [J].
Allison, AC ;
Eugui, EM .
IMMUNOPHARMACOLOGY, 2000, 47 (2-3) :85-118
[3]  
ARMBRUSTER DA, 1994, CLIN CHEM, V40, P1233
[4]   Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration [J].
Bullingham, R ;
Monroe, S ;
Nicholls, A ;
Hale, M .
JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (04) :315-324
[5]   Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients [J].
Bullingham, R ;
Shah, J ;
Goldblum, R ;
Schiff, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 41 (06) :513-516
[6]   Clinical pharmacokinetics of mycophenolate mofetil [J].
Bullingham, RES ;
Nicholls, AJ ;
Kanmm, BR .
CLINICAL PHARMACOKINETICS, 1998, 34 (06) :429-455
[7]   PHARMACOKINETIC DRUG-INTERACTIONS WITH GASTROINTESTINAL MOTILITY MODIFYING AGENTS [J].
GREIFF, JMC ;
ROWBOTHAM, D .
CLINICAL PHARMACOKINETICS, 1994, 27 (06) :447-461
[8]   Gastric emptying in patients on renal replacement therapy [J].
Guz, G ;
Bali, M ;
Poyraz, NY ;
Bagdatoglu, O ;
Yegin, ZA ;
Dogan, I ;
Atasever, T ;
Sert, E ;
Sindel, I .
RENAL FAILURE, 2004, 26 (06) :619-624
[9]   Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2 [J].
Hesselink, DA ;
van Hest, RM ;
Mathot, RAA ;
Bonthuis, F ;
Weimar, W ;
de Bruin, RWF ;
van Gelder, T .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (05) :987-994
[10]   The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGTIA9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients [J].
Kuypers, DRJ ;
Naesens, M ;
Vermeire, S ;
Vanrenterghem, Y .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (04) :351-361